About: High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1999 (uk) im Juli 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1999 (ast) scientific article published on 01 July 1999 (en)
publication date	wds:Q73181635-97CC20BF-6525-4EC0-9D7F-DE5ED60D8612
publication date	1999-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73181635-E48A4B3A-2811-4DA6-AC0F-610BBD061B78
language of work or name	English
author name string	wds:Q73181635-05D364DA-C3EE-45E6-B224-082D79BDE095 wds:Q73181635-0D993127-FCE7-4E7A-8A2A-58B3B457E877 wds:Q73181635-19B3BDCB-260F-4ACB-8F2C-D4EF00AF52A4 wds:Q73181635-332D5B1C-A545-4D63-826A-3CAFBC4DDD0A wds:Q73181635-D0D34D43-14D5-4905-A4F3-5394FFAF99FB wds:Q73181635-D434B681-757B-46AC-BEBD-E0365C9D6380 wds:Q73181635-E9B41E6A-2269-42B9-A946-E13204A78FB8
author name string	B Barlogie P J Stiff J J Crowley D H Vesole D B Johnson J Cromer R Catchatourian
rdfs:label	High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (en) High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (nl)
skos:prefLabel	High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (en) High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (nl)
name	High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (en) High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (nl)
author	wds:Q73181635-3644AEFA-B675-4CD6-A336-466CEFF8CE8F
author	Sydney E. Salmon
title	wds:Q73181635-C75DBE6A-6F63-4BC3-B46D-681552A7FB32
title	High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial (en)
page(s)	wds:Q73181635-F171F252-2DB2-4C40-9E7C-EE89C8FD3FC3
page(s)	2173-2179
instance of	wds:Q73181635-6C9DD736-A875-41C0-B0CC-741C81D40034
instance of	scholarly article
main subject	wds:Q73181635-6D6B1E48-A29E-4BBC-8FB1-810019DAEBB6 wds:Q73181635-A5C12CCC-BD02-48A4-9A44-402C1516FE36
main subject	multiple myeloma phase II clinical trial
PubMed ID	wds:Q73181635-F4562DBB-5040-48C4-AFA6-6681E9A0FD6D
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10561273
PubMed ID	10561273
published in	wds:Q73181635-782AAD1E-BBC4-4CE0-9FE3-653D5174688B
published in	Journal of Clinical Oncology
issue	wds:Q73181635-083E8093-2285-4CFF-A01B-CD01D5B1AB16
volume	wds:Q73181635-7E138C66-5A83-47E4-8044-CDB4C0BB009B
issue	7
volume	17
DOI	wds:Q73181635-3A88A258-C6DB-4014-93A1-0014DC05A7E1
DOI	http://dx.doi.org/10.1200/JCO.1999.17.7.2173
DOI	10.1200/JCO.1999.17.7.2173
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73181635
is cites work of	Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Multiple myeloma Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response Multiple myeloma Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma CR represents an early index of potential long survival in multiple myeloma. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) Plasma cell leukemia Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma Breakthroughs in the management of multiple myeloma Relapsed multiple myeloma Treatment of relapsed and refractory multiple myeloma. Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group.
is cites work of	wds:Q33392245-251E1DFB-73A1-4CB2-BB0E-DF18ABAA1CF9 wds:Q44640634-EB85EBC7-0C75-4E30-BF7A-50C658C46441 wds:Q53259579-E78B7513-D4EC-4832-9646-44C3F1714390 wds:Q50671900-75371D23-B1B1-4B33-AAF5-EB491EAEA484 wds:Q35893993-02324E34-07B7-4F68-886D-B7B6024C25F7 wds:Q42357639-5FF2BAF5-3D14-45DA-AD86-D9F1CEB6D29A wds:Q47369825-2DCE12B6-0A36-45EC-91BB-8AD7ACBA5EA1 wds:Q35194329-66402410-45C7-4648-B3EB-85440261C79E wds:Q49184612-8537A6F9-A0F8-466A-8FBF-50C5662EAA13 wds:Q56212731-9173726C-339A-4CF3-82AF-840C025445F0 wds:Q45001848-1E48F343-44A8-456A-A818-BB9432E60965 wds:Q74267084-0CCFF9A3-9DA7-422C-9CBE-6F2EFC532BED wds:Q35116230-02B75001-9304-40EF-9659-6C4980BB2F99 wds:Q44857535-83F1466A-9430-42BB-8042-04D188E8E12B wds:Q53938789-D9E9698F-C971-411A-9E70-7516EF5ED552 wds:Q58011173-837D9973-7E29-42DD-B1AE-96A046D2827E wds:Q43661033-2EEE64EA-AAF5-4F82-921C-169215857A0D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 176 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software